Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
Top Cited Papers
- 16 April 2003
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 41 (8), 1380-1386
- https://doi.org/10.1016/s0735-1097(03)00121-9
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Bosentan Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertensionThe American Journal of Cardiology, 1999
- Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary HypertensionCirculation, 1997
- Primary Pulmonary HypertensionThe New England Journal of Medicine, 1997
- Doppler echocardiographic index for assessment of global right ventricular functionJournal of the American Society of Echocardiography, 1996
- Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantationJournal of the American College of Cardiology, 1993
- An echocardiographic index for separation of right ventricular volume and pressure overloadJournal of the American College of Cardiology, 1985
- Assessment of right ventricular function using two-dimensional echocardiographyAmerican Heart Journal, 1984